Literature DB >> 12577327

[A controlled clinical study between hepatic arterial infusion with embolized curcuma aromatic oil and chemical drugs in treating primary liver cancer].

J H Cheng1, G Chang, W Y Wu.   

Abstract

OBJECTIVE: To evaluate the effectiveness, toxicity and prospective application of hepatic arterial infusion (HAI) with Embolized Curcuma Aromatic oil (CAO) in treating primary liver cancer (PLC).
METHODS: In the treated group, 32 patients with PLC were treated by HAI with 1-3 ml of embolized CAO and oral administration of Chinese herbal medicine. In the control group, 32 patients with PLC were treated with transcatheter artery chemoembolization (TACE).
RESULTS: In the treated group, one patient attained complete remission (CR) and 13 partial remission (PR), the total effective rate being 43.75%. The level of alpha fetal protein (AFP) turned to normal range in 7 cases and decreased in other 7. In the control group, 10 obtained PR and the total effective rate being 31.25%, AFP level turned to normal in 5 and decreased in 2. There was no statistical significance between the two groups. The incidences of post-embolism syndrome, such as fever, abdominal pain and vomiting were similar between the two groups but no myelosuppression occurred in the treated group with significant difference (P < 0.01) as comparing with that in the control group. The mean survival time, median survival time, 1-, 2- and 3-year survival rate in the treated group was 11.5 months, 10 months, 37.5%, 13.3% and 6.9% respectively, while in the control group was 7.25 months, 6 months, 15.6%, 3.2% and 0 respectively. The treated group was better in mean survival time, median survival time and 1-year survival rate than that of the control group (P < 0.05).
CONCLUSION: HAI with embolized CAO showed a similar favorite effect in treating PLC as that of TACE, but superior than TACE with longer survival time and milder myelosuppression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12577327

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  6 in total

Review 1.  Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: From bench to bedside.

Authors:  Bing Hu; Shuang-Shuang Wang; Qin Du
Journal:  World J Hepatol       Date:  2015-05-28

2.  Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest.

Authors:  Nan Li; Donghai Zheng; Jie Xue; Weixing Guo; Jie Shi; Juxian Sun; Chongde Lu; Weida Zheng; Mengchao Wu; Shuqun Cheng
Journal:  Exp Ther Med       Date:  2015-03-13       Impact factor: 2.447

3.  Safety of Curcuma aromatica oil gelatin microspheres administered via hepatic artery.

Authors:  Shi-Gui Deng; Zhi-Feng Wu; Wei-Ying Li; Zhi-Gang Yang; Gang Chang; Fan-Zhe Meng; Li-Li Mo
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

4.  Cryotherapy for liver metastases.

Authors:  Malgorzata M Bala; Robert P Riemsma; Robert Wolff; Michal Pedziwiatr; Jerzy W Mitus; Dawid Storman; Mateusz J Swierz; Jos Kleijnen
Journal:  Cochrane Database Syst Rev       Date:  2019-07-10

Review 5.  Pharmacological Profile, Bioactivities, and Safety of Turmeric Oil.

Authors:  Adriana Monserrath Orellana-Paucar; María Gabriela Machado-Orellana
Journal:  Molecules       Date:  2022-08-09       Impact factor: 4.927

Review 6.  Chemical Composition and Biological Activities of Essential Oils of Curcuma Species.

Authors:  Noura S Dosoky; William N Setzer
Journal:  Nutrients       Date:  2018-09-01       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.